METHODS
This study comprises 131 patients with localized, locally advanced, and pelvic oligometastatic prostate
cancer treated at our institution. All patients were treated with IMRT between February 2016 and August
2020. Urinary incontinence after the treatment was assessed retrospectively using a standardized
follow-up program based on data available at our center. The urinary incontinence was scored using the
CTCAE version 5.0 scoring system. In univariate analysis, the Mann-Whitney test was used to detect any
association between penile bulb V50 doses and membranous urethral length on urinary incontinence.
RESULTS
Urinary incontinence after the treatment was reported in 17 of 131 patients. The average penile bulb V50
values of patients with incontinence were 28.66 gy and 26.8 in patients who did not have urinary incontinence.
The mean membranous urethral length was 3.01cm in patients with incontinence and 3.34cm
in patients without incontinence. Although these parameters have minimal difference in patients with
and without incontinence, they are not statistically significant (p>0.05 all).
CONCLUSION
Radiation-induced urinary incontinence was not associated with the radiation dose of the penile bulb
and membranous urethral length. However, further studies are essential.
Keywords: Intensity-Modulated Radiotherapy (IMRT); membranous urethra; penile bulb; prostate cancer; urinary incontinence
There are many known anatomical and physiological
parameters related to urinary continence. Rehder et al.[
As we know, radiation treatment affects normal tissue
vasculature near the target volume. We searched
about the effect of this damage on the penile bulb and
related urinary incontinence.
Patients
This retrospective cohort study was composed of 131
patients with localized, locally advanced prostate cancer
and pelvic oligometastatic disease. We excluded
extrapelvic-distant metastatic prostate cancer patients
from the study. All patients were treated with radiotherapy
between February 2016 and August 2020. Of the
131 patients, 30 were those who had undergone radical
prostatectomy (salvage prostatectomy was excluded).
Urinary incontinence that occurred after the treatment
was evaluated. Radiotherapy was delivered using linear
accelerators with 6 MV photons by intensity-modulated
radiotherapy (IMRT). Patients were treated five times
per week at doses ranging from 66 to 76 Gy at the planning
target volume (PTV) using a standard 2 Gy per
fraction. Six of the patients consisted of those treated
with the hypofractionated regimen (2 Gy < per fraction).
In the current patient cohort, 36.6% of patients
had irradiated pelvic lymph nodes as part of therapy.
Setup accuracy was verified during delivery by matching
bony anatomy. Most patients with locally advanced
prostate cancer received adjuvant hormonal treatment.
Diabetes, hypertension, coronary artery disease, and
peripheral artery disease were defined as "vascular diseases".
Other diseases, such as endocrinological and
rheumatological, were described as "other than vascular
disease". These patient characteristics were retrospectively
assessed from detailed patient charts (Table
Target and Organ at Risk Delineation
Endpoints
Statistical Analysis
The high-risk clinical target volume (HR-CTV) consisted
of the prostate with or without the SV, depending on
the estimated risk of SV invasion. Due to the risk of locoregional
metastases, pelvic lymphatics are included in
the low-risk clinical target volume (LR-CTV). The full
bladder was applied as part of the treatment planning.
Patients were instructed to urinate and drink half or one
liter of water one hour before the radiotherapy. The penile
bulb contouring was done with the ESTRO-ACROP
guidelines.[
The grade of urinary incontinence according to CTCAE
v5.0 was evaluated retrospectively using available
patient data between 2016 and 2020. Urinary incontinence
grade 1 was defined as occasional leaking (e.g.,
with coughing, sneezing, etc.) when pads were not
indicated, while grade 2 was defined as spontaneous
leaking when pads were indicated. In addition, the operation
intervention is only applied to grade 3. Urinary
incontinence was evaluated for the first six months after
treatment. Late urinary incontinence and recovery
of incontinence were not evaluated.
In univariate statistical analysis, the Mann-Whitney
test was used to detect any association between penile
bulb V50-V60 doses and membranous urethral length
on urinary incontinence. Besides, the variables of age,
comorbidity, operation, hormone therapy, bladder, and
trigonum doses were compared to perform a univariate
analysis. p value < 0.05 was considered significant. The
statistical analysis was performed using IBM SPSS 22.0.
Although there is minimal change in these parameters
in patients with incontinence, they are not
statistically significant (p>0.05 all). The variables of
age, comorbidity, operation, hormone therapy, bladder,
and trigonum doses were compared to perform
a univariate analysis. The only association with incontinence
was found with radical prostatectomy
(p=0.021) (Table
There is an idea that physiological contraction of the bulbospongiosus muscle increases pressure in the bulb of the penis (as blood is not compressible) and consecutively leads to additional contraction of the urethral lumen. A well-vascularized penile bulb is an essential factor in this mechanism. Radiotherapy reduces the blood supply to these anatomic regions, and our study was based on this idea.
The proximal male urethral bulb is an integrated
part of the urinary continence mechanism, especially
during increased physical activity. Several clinical
studies support this view.[
We have found no relation between urinary incontinence
and penile bulb radiation doses. There
could be several explanations for this result. The
most important one is that we have a short period of
follow-up time data retrospectively (six months), so
there was no evaluation of late urinary incontinence
and recovery. Just like the other factors, it should be
kept in mind that penile bulb radiation dose may be
associated with incontinence recovery. The second is
that we do not use any side effect scoring questionnaires.
The clinician"s patient records were used for
grading urinary incontinence (CTCAE v5.0) retrospectively.
This means there may be missing records.
Ethics Committee Approval: The study was approved by the Gazi University Ethics Committee (no: E-77082166- 604.01-1006859, date: 31/07/2024).
Authorship contributions: Concept - M.A.; Design - M.A., Ş.D.; Supervision - M.A., Ş.D.; Materials - Ş.D.; Data collection and/or processing - Ş.D., M.E.Ş.; Data analysis and/or interpretation - Ş.D.; Literature search - Ş.D.; Writing - Ş.D.; Critical review - M.A., Ş.D.
Conflict of Interest: All authors declared no conflict of interest. Use of AI for Writing Assistance: Not declared.
Financial Support: None declared.
Peer-review: Externally peer-reviewed.